New Constructs CEO David Trainer appeared on CNBC’s Santelli Exchange on Wednesday May 25, 2016 to discuss the credibility of non-GAAP earnings and its damaging effects on shareholders.
Over the weekend, Barron’s magazine featured our research for the fourth time in 2016 and 20th time since 2014. This time, Barron’s featured our research on Valeant Pharmaceuticals (VRX).
In this webinar, CEO David Trainer, will discuss our propriety research system, what makes us better, and how we can help protect investors, directors, and auditors.
We are proud to announce that New Constructs has been ranked the #1 LTM Analyst per SumZero Rankings.
On Tuesday (3/15/16) SumZero prominently featured our research on Valeant Pharmaceuticals (VRX) as the stock dropped over 50% in one day
This past weekend, Barron’s magazine featured our research for the second time in 2016 and 18th time since 2014. This time, Barron’s featured research from our Danger Zone report, and recent price update on LinkedIn (LNKD).
CEO David Trainer sat down with Chuck Jaffe of Money Life and MarketWatch.com to talk about our Danger Zone pick this past week: Square, Inc. (SQ)
This past weekend, Barron’s magazine featured our research for the sixth time in 2015 and 15th time since 2014.
New Constructs has been selected as a Finalist of the BBVA Open Talent 2015 competition.
Join CEO David Trainer to learn exactly how New Constructs allows you to grow your wealth the smart way. This webinar was hosted by Interactive Brokers as part of their Traders Webinars.
In case you missed it, or in case you wanted to watch it again, here is our live webinar from this week.
Our Company Valuation models are very sophisticated discounted cash flow and earnings quality models.
An enormous amount of works goes into every model. I wish I could offer a short-cut (beyond our ratings and reports) for understanding our models.
Always flattered when a journalist, especially one as famous and respected at Mr. Taibbi, references my work. His article “Bank of America In Trouble?” incorporated the meat of my “Raising Fees Is A Desperate Measure: Sell BAC” article.
Fox Business News features my focus on the Real Earnings Season that is overlooked by most everyone in the market.
The Portfolio Management Rating of a fund is based on the aggregated ratings of the securities it holds as well as its overall Asset Allocation. When analyzing equity funds, we use New Constructs’ stock ratings, which are regularly featured as among the best by Barron’s over the past three years.
Here is a free copy of our report on AAPL for Ask Matt readers.
AAPL gets our “Very Attractive” rating because its economic earnings are positive and rising, it has one of the highest returns on invested capital (ROIC) in the world. At the same time, it’s stock price reflects very low expectations for future earnings growth.
High dividend yields are NOT enough to warrant investing in the utilities sector.
Too many investors put their hard-earned money in utility stocks with the assumption that relatively high-yielding dividends from stable business make a good investment.
The real question that investors in any equity security must ask is: does my expected return from a stock justify the risk of investing in it?
Similar to my prior interviews on SBUX, I found it easy to make the bear case for a stock that is as expensive as Starbucks (SBUX). As my regular readers know, when I say “expensive”, I back that up with details such as: to justify its $40 stock price (closing price from prior day), SBUX had to grow profits at 10% compounded annually for more than 25 years.
In addition to my stock-brawl interview on Thursday (9/29/11), I have commented to the media on Starbucks (SBUX) many times. Below is a list (with links) to my past opinions/comments on SBUX.
I do not think so. The question, however, is not so much about what directors ignore. You cannot ignore something about which you are unaware.
The real issue is that most directors and investors are simply unaware of the many one-time items because they are buried deep in the annals of footnotes in annual reports or 10-K filings.
Page 1 of 2